ArticleAnticancer research2012
CSF-1R up-regulation is associated with response to pharmacotherapy targeting tyrosine kinase activity in AML cell lines.
Article in Anticancer research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 13 citations in OpenAlex.
- Generalized information criteria for personalized gene network inference.Frontiers in genetics · 2025Article
- Single-Nuclei Characterization of Lacrimal Gland in Scopolamine-Induced Dry Eye Disease.Investigative ophthalmology & visual science · 2024Article
- Immunotherapy Targeting Tumor-Associated Macrophages.Frontiers in medicine · 2020Review
- Article
- Synthesis and Evaluation of Novel 2-Pyrrolidone-Fused (2-Oxoindolin-3-ylidene)methylpyrrole Derivatives as Potential Multi-Target Tyrosine Kinase Receptor Inhibitors.Molecules (Basel, Switzerland) · 2017Article
- Progress in tumor-associated macrophage (TAM)-targeted therapeutics.Advanced drug delivery reviews · 2017Review
- Inhibition of the colony-stimulating-factor-1 receptor affects the resistance of lung cancer cells to cisplatin.Oncotarget · 2016Article
- Sunitinib impedes brain tumor progression and reduces tumor-induced neurodegeneration in the microenvironment.Cancer science · 2015Article
- Personalising pancreas cancer treatment: When tissue is the issue.World journal of gastroenterology · 2014Review
- Mobility but Not Balance Limitations Are Associated With Cognitive Decline among Older Hispanics.Gerontology & geriatric medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
backgroundThe oncogenic potential of colony stimulating factor 1 receptor (CSF-1R) has been well described, while its relevance for human acute myelogenous leukemia (AML) is still undetermined. In a recent clinical trial for AML, sunitinib was found to hold potential therapeutic benefit, however, the mechanism for this remains unknown. MATERIALS AND
methodsIn this study, we treated three myeloid cell lines, Mono-Mac 1, THP-1, and U937, with sunitinib, and a small-molecule CSF-1R inhibitor (cFMS-I) to test the anticancer effect of such treatment.
resultsMono-Mac 1 cells had inhibited proliferation and extracellular-signal regulated kinase activity as a result of CSF-1R inhibition and a dose-dependent increase in CSF-1R expression with both sunitinib and cFMS-I.
conclusionOur results suggest potential for CSF-1R as an important target of sunitinib or other similar drugs. Future study of CSF-1R may produce more targeted therapeutic approaches and aid in the development of personalized medicine for AML.
Indexed as
Identifiers
22399609PMC3601026W2096729460What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.